Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes

Journal of Neuro-Oncology

Volumn 32, Issue 1, 1997, Pages 29-38

  Rice, Charles D ^a   Baldwin, Nevan G ^a   Biron, Roland T ^a   Bear, Harry D ^a   Merchant, Randall E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

interferon; Activation; Culture; Cytotoxicity; Glioma; Immunotherapy; Lymphocyte; Signal transduction

Indexed keywords

BRYOSTATIN 1; CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; IONOMYCIN; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL SECRETION; CELL SUSPENSION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; FEMALE; GLIOMA; IMMUNOTHERAPY; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CELL COMMUNICATION; CHROMIUM RADIOISOTOPES; CYTOKINES; FEMALE; GLIOMA; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPH NODES; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031040474     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005771717409     Document Type: Article

References (47)

1. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD : Immunobiology of gliomas. Sem Oncol 13: 94-109, 1986
2. Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neuro-Oncol 8: 173-188, 1990
3. Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725-732, 1988
4. Grimm EA, Brunner JM, Carinhas J, Koppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP: Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multi-forme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother 32: 391-399, 1991
5. Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW: Successful treatment of malignant rat glioma with cytotoxic T-lymphocytes. Neurosurgery 31: 528-533, 1992
6. Paine JT, Janda H, Yamasaki T, Yamashita J, Miyatake S: Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors. Neurosurgery 18: 766-772, 1986
7. Sawamura Y, Hosokawa M, Kuppner, Kobayashi H, Aida T, Abe H, de Tribolet N: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49: 1843-1849, 1989
8. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-De-Masters B, Bellgrau D : Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Nat Acad Sci USA 87: 9577-9581, 1990
9. Redd JM, Lagarde A-C, Kruse CA, Bellgrau D: Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 34: 349-354, 1992
10. Holladay FP, Choudhuri R, Heitz T, Wood GW: Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80: 90-96, 1994
11. Holladay FP, Wood GW: Generation of cellular immune responses against a glioma-associated antigen(s). J Neuroimmunol 44: 27-32, 1993
12. Barth RJ, Mule JJ, Asher AL, Sanda MG, Rosenberg SA: Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-γand tumor necrosis factor. J Immunol Method 140: 269-279, 1991
13. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, LeMevel B: High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10: 404-411, 1991
14. Tzeng JJ, Barth RF, Orosz CG, James SM: Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51: 2372-2378, 1991
15. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA : T-cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 146: 4414-4420, 1991
16. Nijhuis EWP, Kemenade EW, Figdor CG, Van Lier RAW: Activation and expansion of tumor-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol Immunother 32: 245-250, 1990
17. Yanelli JR, Crumpacker DB, Good RW, Friddell CD, Poston R, Horton S, Maleckar JR, Oldham RK: Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy. J Immunol Methods 130: 91-100, 1990
18. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD: Activation and growth of murine tumor-specific T-cells which have in vivo activity with Bryostatin-1. Cancer Res 52: 548-553, 1992
19. Tuttle TM, McCrady CW, Igge TH, Mozhdeh S, Bear HD: γ-interferon plays a key role in T-cell-induced tumor regression. Cancer Res 53: 833-839, 1993
20. Kraft AS, Smith JB, Berkow RL: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester induced differentiation of human promyelocytic progenitor cells HL-60. Proc Natl Acad Sci USA 83: 1334-1338, 1986
21. Hoover SK, Frank JL, McCrady CW, McKinnon JG, Bear HD: Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers. J Surg Oncol 46: 117-124, 1991
22. Baldwin NB, Rice CD, Tuttle TM, Bear HD, Hirsch JI, Merchant RE: Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J Neuro-Oncol, in press, 1996
23. Merchant RE, Baldwin NB, Rice CD, Bear HD: Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res, in press, 1995
24. Elswick RK, Chinchilli V: A mixture of the MANOVA and GMNOVA models. Commun Statist 14: 3075-3089
25. Ortaldo JR, Longo DL: Human natural lymphocytic effector cells: Definition, analysis of activity, and clinical effectiveness. JNCI 80: 999-1010, 1988
26. Timonen T, Ortaldo JR, Herberman RB: Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153: 569-582, 1981
27. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF: Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578, 1990
28. Ellison MD, Povlishock JT, Merchant RE: Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 47: 5765-5770, 1987
29. Rosenstein M, Ettinghausen SE, Rosenberg SA : Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137: 1735-1742, 1986
30. Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by intracerebral injection of human recombinant interleukin-2. Neurosurgery 25: 202-208, 1989
31. Ames IH, Gagne GM, Garcia AM, John PA, Scatorchia GM, Tomar RH, McAfee JG: Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice. Cancer Immunol Immunother 29: 93-100, 1989
32. Schoof DD, Jung SE, Eberlein TJ : Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody. Int J Cancer 44: 219-224, 1989
33. Chou T, Chang A, Shu S: Generation of therapeutic T lymphocytes from tumor bearing mice by in vitro sensitization. Culture requirements and characterization of immunospecificity. J Immunol 140: 2453-2461, 1988
34. Gervois N, Heuze F, Diez E, Jotereau F: Selective expansion of specific anti-tumor CD8+ cytotoxic T-lymphocyte clones in bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T-cell receptor gene rearrangements. Eur J Immunol 20: 825-831, 1990
35. Hines DL: Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells. Cancer Immunol Immunother 28: 241-247, 1989
36. Chang AE, Geiger JD, Sondak VK, Shu S: Adoptive cellular therapy of malignancy. Arch Surg 128: 1281-1290, 1993
37. Shu S, Sussman JJ, Chang AE: In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents. J Immunother 14: 279-285, 1993
38. Rice CD, Merchant RE: Systemic treatment with murine recombinant interleukin-1β inhibits the growth and progression of malignant glioma in the rat. J Neuro-Oncol 13: 43-55, 1992
39. Gerrard TL, Dyer DR, Zoom KC, Nedden DZ, Siegel JP: Modulation of class I and class II histocompatibility antigens on human T cell lines by IFN-γ. J Immunol 140: 3450-3455, 1988
40. Wong GHW, Clark-Lewis I, McKimm-Breschkin JL, Harris AW, Schrader JW: Interferon-γ induces enhanced expression of Ia and H-2 antigen on lymphoid, macrophage, and myeloid cell lines. J Immunol 131: 788-793, 1983
41. Flyer DC, Burakoff SJ, Faller DV: Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. J Immunol 135: 2287-2292, 1985
42. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ: Interleukin-2 mediated immune interferon (IFN-γ) production by human T cells and T cell subsets. J Immunol 130: 1784-1789, 1983
43. Place JL, Russel SW, Torres BA, Johnson HM, Gray PW: Recombinant mouse γ-interferon induces the prime step in macrophage activation for tumor cell killing. J Immunol 130: 2001-2013, 1983
44. Giovarelli M, Santoni A, Jemma C, Musso T, Ginffrida AM, Cavallo G, Landofo S, Forni G: Obligatory role of IFN-γ in induction of lymphokine-activated and T-lymphocyte killer, but not in boosting of natural cytotoxicity. J Immunol 141: 2831-2836, 1988
45. Miyatake S, Nishihara K, Kikuchi H, Yamashita J, Namba Y, Hanaoka M, Watanabe Y: Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-γ gene. JNCI 82: 217-220, 1990
46. Nishihara K, Miyatake K, Sakata T, Yamashita J, Kikuchi H, Kawade Y, Zu Y, Namba Y, Hanoka M, Watanabe Y: Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse γ-IFN complementary DNA. Cancer Res 48: 4730-4735, 1988
47. Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B: Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med 164: 1206-1225, 1986